ASCO
The company analyzed MRD status in samples from a prior failed study, showing a significant benefit from the drug for ctDNA-positive patients.
Researchers Highlight Progress in Head and Neck Cancer MRD at ASCO, but Results Remain Preliminary
Premium
Clinicians said that residual disease tests could be of great benefit to this population, but advancing technologies will still have to prove themselves.
With New Validation Data, BillionToOne Boosts Commercial Prospects of Therapy Selection Assay
Premium
The Northstar Select comprehensive genomic profiling test uses BillionToOne's proprietary Quantitative Counting Template technology for solid tumors.
As ctDNA testing for early-stage tumors gains traction, clinicians eagerly await more clarity on overall utility and the potential value of increased sensitivity.
The company's PreveCol test uses molecular biomarkers and clinical features to detect colorectal cancer and precancerous lesions from blood samples.